Have you come across such a situation? At times, we have been informed by Sponsors / CROs that it is more critical to conduct a Study Feasibility exercise rather than the Investigator Sites’ assessments. This is because there could be some typical indications / disease profiles / protocol procedures which may be difficult or close to impossible to be conducted in a country like ours. The reasons for these could vary from the regulatory environment to the genetic pool that is prone to the particular disease profile under discussion.
We at Consortium Clinical
Research, provide the valuable Study Feasibility research reports to our Sponsors be it international or domestic, stating whether it is possible to procure adequate regulatory approvals and / or to ensure adequate patient numbers in that particular study from within the country.